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Differentiation of mammary epithelium in vivo requires signaling through prolactin- and ErbB4/HER4-dependent
mechanisms; how these pathways intersect is unknown. We show herein that HC11 mouse mammary cells undergo
ErbB4-dependent lactational differentiation. Prolactin and the ErbB4 ligand HB-EGF each induced STAT5A activation,
expression of lactogenic differentiation markers, and lumen formation in three-dimensional Matrigel cultures in HC11
cells. ErbB4 undergoes ligand-dependent transmembrane domain cleavage at Val-675, releasing a soluble 80-kDa intra-
cellular domain (s80HER4) that localizes to nuclei; the physiological relevance of s80HER4 is unknown. A HER4V675A mutant
abolishing transmembrane cleavage impaired STAT5A activity, lactogenic gene expression, and lumen formation.
Kinase-dead HER4KD was neither cleaved nor able to induce differentiation of HC11 cells. Without treating HC11 cells
with prolactin or HB-EGF, s80HER4 (expressed from a cDNA construct) localized to the nucleus, activated STAT5A, and
induced three-dimensional lumen formation. Nuclear localization of exogenous s80HER4 required intact kinase activity of
s80HER4, as did activation of STAT5A. In contrast, nuclear localization of s80HER4 and STAT5A activation did not require
the 16-amino acid region of the ErbB4 intracellular domain specific to the Cyt-1 isoform of ErbB4, and absent in the Cyt-2
isoform. These results suggest that s80HER4 formation contributes to ErbB4-dependent differentiation of mammary
epithelial cells.
INTRODUCTION
Growth factors and hormones control the signaling networks
that regulate the physiological cycles of proliferation, differen-
tiation, and involution in the mammary epithelium. Alter-
ations in these signaling networks could therefore affect the
regulation of these processes, resulting in pathological conse-
quences including cancer (Chodosh, 2002). Each member of the
HER/ErbB family of receptor tyrosine kinases (RTKs) regu-
lates different aspects of mammary development (Stern, 2003).
The four family members, ErbB1/EGFR/HER1 (epidermal
growth factor receptor), ErbB2/Neu/HER2, ErbB3/HER3,
and ErbB4/HER4, each contain ligand-binding extracellular,
transmembrane domain and intracellular tyrosine kinase
domains. The ErbB receptors exhibit ligand-inducible dimer-
ization, transphosphorylation, and tyrosine kinase activity,
with the exception of ErbB3, for which tyrosine kinase ac-
tivity has not been observed. Either homo- or heterodimers
between family members can occur, with ErbB2 being the
preferred heterodimeric partner. ErbB2 does not bind any
conventional ligand, relying on ligand binding to ErbB1,
ErbB3, or ErbB4 for tyrosine kinase induction. The multitude
of potential ligand-driven ErbB dimers generates a variety of
cellular responses.
ErbB receptors are activated by two ligand families: the
epidermal growth factor (EGF) family (EGF, transforming
growth factor- [TGF], amphiregulin [AR], heparin bind-
ing-EGF [HB-EGF], epiregulin, and betacellulin) and the
neuregulins (heregulin [neuregulin-1], neuregulin-2, -3, and
-4). In the breast epithelium, ErbB1 is activated by EGF, AR,
and TGF, and together they contribute primarily to ductal
proliferation. HB-EGF binds to both ErbB1 and ErbB4, and
contributes to differentiation via ErbB4. The neuregulins
bind to both ErbB3 and ErbB4. Heregulin (HRG) regulates
both proliferation and differentiation of breast epithelial
cells (Marte et al., 1995; Yang et al., 1995; Jones et al., 1996).
ErbB4 signaling impairs growth of many human breast
cancer cells (Sartor et al., 2001) and promotes differentiation
of murine mammary glands (Jones et al., 1999; Long et al.,
2003; Tidcombe et al., 2003). In vivo, ErbB4 expression and
activity are lowest during phases of epithelial cell prolifer-
ation (puberty and early pregnancy) and highest during
phases of differentiation (late pregnancy and early lactation;
Schroeder and Lee, 1998). Mammary glands from mice that
lack ErbB4 activity have lactational defects due to an im-
paired program of differentiation, measured by decreased
expression of milk proteins and decreased activity of
STAT5A, a transcription factor required for lactation (Jones
et al., 1999; Long et al., 2003; Tidcombe et al., 2003). STAT5A
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deficiency results in failed lactogenesis, a phenotype remi-
niscent of ErbB4-deficient mammary glands (Liu et al., 1997;
Shillingford et al., 2001; Cui et al., 2004).
Many ErbB4-positive breast cancers, as well as normal
human and mouse mammary tissue, exhibit nuclear local-
ization of ErbB4 (Srinivasan et al., 2000; Abd El-Rehim et al.,
2004; Junttila et al., 2005). Recent work by several groups has
described the mechanism by which specific ErbB4 splice
variants translocate to the nucleus. Treatment of cells with
ligand results in stepwise proteolysis of the JMa splice vari-
ant of ErbB4 (Elenius et al., 1997; Rio et al., 2000; Cheng et al.,
2003), beginning with cleavage by TACE (tumor necrosis
factor- converting enzyme) and shedding of the ectodo-
main (Carpenter, 2003). This leaves an 80-kDa ErbB4 frag-
ment tethered to the membrane (m80HER4). A second proteo-
lytic event in the transmembrane domain of ErbB4, carried out
by a -secretase (Ni et al., 2001, 2003; Lee et al., 2002), liberates
the soluble cytoplasmic domain (s80HER4) with an active ty-
rosine kinase into the cytosol (Linggi et al., 2005). The JMb
splice variant lacks the TACE cleavage sequence (Elenius et al.,
1997; Rio et al., 2000). In a recently published study, mutation of
a transmembrane valine residue (a putative -secretase cleav-
age site) impaired ErbB4 cleavage (Vidal et al., 2005). Because
TACE-mediated cleavage of ErbB4 is prerequisite for -secre-
tase cleavage, it is predicted that the JMb isoform would not
yield s80HER4.
Localization of s80HER4 to both the cytosol and nucleus has
been previously described. There are three nuclear localization
sequences (NLS) within s80HER4, and three putative nuclear
export sequences (Carpenter, 2003). Mutation of one of these
NLS sequences prevented nuclear translocation of s80HER4
(Williams et al., 2004). The function of nuclear s80HER4 is not
known, although recent reports suggest that s80HER4 may as-
sociate with the transcription factors STAT5A in the nucleus
and transactivate gene expression (Williams et al., 2004; Vidal et
al., 2005). Additionally, nuclear association of ErbB4 with the
transcription factor YAP suggests that s80HER4 may participate
in transcriptional regulation (Komuro et al., 2003).
In this report we describe experiments using the mouse
mammary epithelial cell line HC11 as a model of mammary
differentiation to investigate ErbB4 and its cleavage product,
s80HER4, in transmitting differentiation signals. Multiple as-
pects of differentiation required ErbB4 kinase activity and
cleavage of ErbB4 to produce s80HER4. Expression of s80HER4
was itself sufficient to initiate differentiation, whereas kinase-
dead s80KD was unable to associate with or phosphorylate
STAT5A, to differentiate HC11 cells, and accumulate in nuclei.
MATERIALS AND METHODS
Cell Culture
HC11 cells and all derivatives were cultured at 5% CO2 in growth media
(DMEM/F12 [Invitrogen Life Sciences, Carlsbad, CA] supplemented with
10% fetal bovine serum [FBS], EGF [10 ng/ml; Invitrogen], insulin [5 g/ml;
Sigma-Aldrich, St. Louis, MO]), and hydrocortisone (1 g/ml; Sigma-Aldrich)
unless otherwise indicated. For some experiments, cells were cultured over-
night in priming media [serum-free/EGF-free DMEM-F12 media supple-
mented with hydrocortisone (1 g/ml) and insulin (5 g/ml)] for 2 d and
then treated for the indicated time points (30 min-2 d) with PRL (5 g/ml;
Sigma-Aldrich), EGF (10 ng/ml; R&D Systems, Minneapolis, MN), HRG1
(10 ng/ml; a gift from Genentech, San Francisco, CA), HB-EGF (10 ng/ml;
Sigma-Aldrich). For three-dimensional (3D) cultures, 5  104 cells in 100 l
priming media supplemented with the indicated factors were resuspended in
100 l cold growth factor-reduced Matrigel (BD Biosciences, San Jose, CA)
and plated in one well of a 96-well plate precoated with growth-factor–
reduced Matrigel. Cultures were allowed to polymerize at 37°C for 1 h, then
overlaid with 50 l priming media to prevent drying. Cells were cultured 10
d, then fixed in 1% paraformaldehyde (PFA) in phosphate-buffered saline
(PBS), pH 7.4, stained with DAPI (Vector Laboratories, Burlingame, CA),
and photographed with a Zeiss LCM210 using Scion Image 2.0 software
(Thornwood, NY).
Western Analysis and Immunoprecipitation (IP)
Western analysis and immunoprecipitations (IPs) from whole cell lysates
were performed as previously (Sartor et al., 2001) using the following anti-
bodies: rabbit polyclonal anti-ErbB1, ErbB3, and ErbB4 (C-terminus) were
generated in this laboratory and have been previously described (Sartor et al.,
2001); ErbB2 (Neomarkers, Fremont, CA); STAT5A and phospho-Tyr 694
STAT5 A/B (Zymed Laboratories, South San Francisco, CA), ErbB4 (HFR;
Neomarkers), GFP, -casein, -tubulin, c-jun, and phosphotyrosine (PY20;
Santa Cruz Biotechnologies, Santa Cruz, CA), p44/42 (Cell Signaling Tech-
nology, Beverly, MA). NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Pierce Biotechnology, Rockford, IL) were used to separate nuclear and cyto-
plasmic compartments of cells, according to the manufacturer’s protocol. For
membrane versus cytosolic separation, cells (108) were lysed in ice-cold buffer
A (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, and 250 mM sucrose,
1 mM sodium vanadate, and 1 protease inhibitor cocktail; Roche, Indianap-
olis, IN) using a 19-gauge needle. The samples were centrifuged at 1500  g,
4°C for 10 min to pellet nuclei and cell debris. Membranes were pelleted from
supernatants by centrifugation for 1 h at 10,000  g in a Beckman ultracen-
trifuge. The resultant supernatant represented cytosolic fractions. The pellets,
representing membrane fractions, were resuspended in 10 mM Tris-HCl, pH
7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 250 mM sucrose, 1 mM
sodium vanadate, and 1 protease inhibitor cocktail for 45 min at 4°C and
then cleared by centrifugation.
Immunohistochemistry
Cells grown on glass chamber slides were fixed in 1% PFA, permeabilized in
methanol:dimethylsulfoxide (1:1), washed twice with PBS, blocked for 1 h in
3% gelatin/0.2% Tween-20 in PBS (PBST), and then incubated overnight at
4°C in STAT5A antibody or ErbB4 antibody (1:70 in PBST). Slides were
washed in PBST, incubated for 1 h at room temperature in rhodamine or
Alexa488-conjugated anti-mouse IgG, washed, and mounted with DAPI
Vectashield (Vector Laboratories). Cells were photographed using the Zeiss
LCM 210 microscope and Scion Image 2.0 software (Scion, Frederick, MD).
Plasmids and Mutagenesis
pLXSN-HER4 and pLXSN-HER4KD cDNA have been described previously
(Sartor et al., 2001). The V675A mutation of the P1 valine (residue 675) was
performed by PCR-assisted site-directed mutagenesis using the primer 5-
TTATGCTAGAAGGAAGAGCATCAAA-3 (mutated residue underlined)
and the Quick-change Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA). The intracellular domain of HER4, s80HER4 (residues 676-1308) fused at
the NH2-terminus with GFP was subcloned into pcDNA4 (Invitrogen). Mu-
tagenesis of residue 751 in the ATP-binding pocket of s80 was performed in
pcDNA4-s80 as described above using the primer 5 AGAATCCGAATAGC-
CACAGGAATCTTCAC-3, resulting in a K-to-R mutation (mutated nucleo-
tides underlined). PcDNA4-s80Cyt2 was generated from a PmeI fragment of
pcDNA3–4ICD-Cyt2, provided by Dr. Klaus Elenius (Junttila et al., 2005),
encoding s80Cyt2.
Transfections and Luciferase Assays
Cells, 5  105, were seeded into a 10-cm dish 24 h before transfection. Cells
were transfected in 5 ml serum-free DMEM with 12 l Fugene6 Transfection
Reagent (Roche) and 5 g plasmid DNA. For generation of stable cell lines,
cells were selected with either G418 (500 g/ml) or zeocin (1 g/ml). For
transient transfection assays, cells were treated with factors in serum-free
media 24 h after transfection. Cells were harvested 48 h after transfection.
Luciferase assays were performed using 200 g protein (Luciferase Assay Kit;
Promega, Madison, WI) according to the manufacturer’s instructions.
Reverse Transcription-Polymerase Chain Reaction
Total RNA was extracted using TRIzol Reagent (Invitrogen). RT-PCR was
performed using total RNA (1 g per 50 l reaction) in the One-Step RT-PCR
kit (Qiagen, Valencia, CA) according to manufacturer’s suggestions using
gene-specific primers: mouse -casein (forward 5ACT ACA TTT ACT GTC
TCC TCT GAG and reverse 5 GTG CTA CTT GCT GCA GAA AGT ACA G,
producing a 534-base pair amplicon); mouse keratin 18 (forward 5 CGC ATC
GTC TTG CAG ATC GAC A, and reverse 5 GCT GAG ACC AGT ACT TGT
CCA G, producing a 375-base pair amplicon). RT-PCR products were re-
solved on 2% agarose gels.
RESULTS
ErbB4 Ligands Induce Differentiation of HC11 Cells
Evidence from transgenic mouse models demonstrated the
requirement for ErbB4 in lactogenic differentiation of the
mammary gland. We used the HC11 cell line, derived from
the mammary gland of a female Balb/C mouse at midpreg-
nancy, as an ex vivo model of mammary epithelial cell
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differentiation to determine the role of s80HER4 in this pro-
cess. HC11 cells have been widely used as a model of pro-
lactin (PRL)-induced mammary epithelial cell differentia-
tion. To determine if ErbB4-activating ligands were able to
induce a differentiated phenotype in HC11 cells, we initially
treated cells with HRG, HB-EGF, and PRL to observe the
effects of these ligands on STAT5A activation, using phos-
phorylation at Tyr-694 and nuclear translocation as surro-
gate markers of STAT5A activity. STAT5A was phosphory-
lated at Tyr-694 after a 30 min treatment with PRL and with
the ErbB4 ligands HRG and HB-EGF (Figure 1A). Although
STAT5A was primarily cytoplasmic in serum-starved HC11
cells, treatment with PRL for 30 min resulted in nuclear
translocation of STAT5A (Figure 1B). HRG and HB-EGF also
induced nuclear translocation of STAT5A (Figure 1B). Li-
gand-induced STAT5A-mediated transcriptional activation
was examined in transient transfection assays using a re-
porter construct comprised of residues (294 to 1) of the
human -casein gene driving the Photinus luciferase cDNA
(pcasein-lux). This region of the -casein gene harbors
STAT5A DNA-binding sites (Winklehner-Jennewein et al.,
1998). PRL treatment for 24 h increased luciferase activity
7.1-fold compared with untreated cells, as did HRG (6.7-fold)
or HB-EGF (8.3-fold; Figure 1C). Cells treated with EGF, an
ErbB1-specific ligand, induced luciferase activity to a lesser
extent (2.1-fold), suggesting that ErbB1 homodimers are
not responsible for maximal induction of STAT5-mediated
transcription.
-casein and -lactalbumin are milk proteins whose ex-
pression is induced upon lactogenic differentiation of HC11
cells. Thus, we examined RNA expression of the endoge-
nous -casein and -lactalbumin genes as a physiological
marker of lactogenic differentiation. RT-PCR analysis dem-
onstrated that PRL treatment (48 h) induced -casein and
-lactalbumin mRNAs. HRG and HB-EGF also induced -casein
and -lactalbumin mRNAs (Figure 1D). Expression of keratin
18 (K18) transcripts was detected in all samples. Expression
of the -casein protein was induced in HC11 cells treated
48 h with PRL or HRG (Figure 1E). These results suggest that
ErbB4-activating ligands (HRG and HB-EGF) result in acti-
vation of STAT5A similar to PRL. Because neither ErbB2 nor
ErbB3 bind to HB-EGF and EGF did not result in high levels
of STAT5A-mediated transcription or -casein expression,
this indirectly suggests that ErbB4 signaling is responsible
for the nuclear translocation and transcriptional activity of
STAT5A in response to these ligands. The results, however,
Figure 1. ErbB4 ligands activate STAT5A in HC11 cells. (A) STAT5A immunoprecipitates (IP) from HC11 cells cultured in serum-free (SF)
media with PRL, HRG, or HB-EGF for 30 min were analyzed by immunoblot (IB) with indicated antibodies at the right of each panel. (B)
Immunohistochemistry detecting STAT5A localization in serum-starved HC11 cells treated with indicated factors for 30 min. Scale bar, 100
m. (C) HC11 cells transfected with the STAT5A-responsive promoter, pcasein-lux, and cultured 48 h in SF media. Agonists were added
as indicated for the final 24 h of the experiment. Luciferase activity is shown as the average relative light units (RLU) per g of total protein 
SD. Experiments were repeated three times, with each sample being analyzed in triplicate. *p  0.003 versus control. **p  0.01 versus
control. Student’s unpaired t test. (D and E) Confluent HC11 cells cultured in priming media for 2 d and then in priming media  PRL, HRG,
or HB-EGF (where indicated) for an additional 2 d. (D) RT-PCR analysis used primer sets to detect expression of -casein, -lactalbumin
(-lact.), or keratin 18 (K18). For each sample analyzed, the reverse transcriptase (RT) was either included () or left out () of the reaction.
(E) Whole cell extracts were analyzed by Western analysis using antibodies against -casein and -tubulin. (F) HC11 cells were stably
transfected with a pLXSN-derived construct encoding human ErbB4/HER4 or a variant harboring a point mutation at lysine 751 [rendering
the product kinase-dead (HER4KD)]. Pooled clones of HC11-HER4 and HC11-HER4KD cells were analyzed by Western blot to detect tyrosine
phosphorylation of ErbB4 immunoprecipitates. Serum-starved cells were treated with HB-EGF for 10 min. Blots were stripped and reprobed
with a mAb against ErbB4. (G) Pooled clones of HC11-pLXSN, HC11-HER4, or HC11-HER4KD cells were transfected with pcasein-lux and
then treated with PRL or HB-EGF for 24 h, measuring luciferase activity as described above.
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do not discriminate between the possibilities that ErbB4 is
functioning as a homodimer or in heterodimeric concert
with other ErbB receptors.
To determine the effects of impaired ErbB4 activity on
HRG and HB-EGF–induced signaling in HC11 cells, we
generated pools of stable cell lines expressing overexpress-
ing wild-type HER4 or kinase-dead HER4KD. Ligand-in-
duced ErbB4/HER4 tyrosine phosphorylation was impaired
in cells overexpressing HER4KD (HC11-HER4KD; Figure 1F).
HC11-HER4KD cells were transfected with the pcasein-lux
(Figure 1G). As a control for ectopic overexpression of
HER4KD, HC11-HER4 cells were examined in parallel. Treat-
ment of HC11-HER4 cells with PRL resulted in a 12.4-fold
increase in luciferase activity, somewhat greater than the
levels of PRL-induced luciferase activity seen in HC11-
pLXSN cells (Figure 1G). This suggests that wild-type HER4
overexpression may enhance PRL-mediated STAT5A activ-
ity. In contrast, treatment of HC11-HER4KD cells with PRL
induced luciferase activity 4.8-fold, a decrease when com-
pared with luciferase acitivity from PRL-treated HC11-
pLXSN cells, suggesting that HER4KD expression partially
impaired PRL-dependent activation of this promoter. HB-
EGF-induced STAT5A activation was similarly increased in
HC11-HER4 cells, and expression of HER4KD abolished pro-
moter transactivation in response to HB-EGF (Figure 1G).
Morphological Differentiation of HC11 Cells in Response
to ErbB4
HC11 cells were embedded in serum-free, growth factor-
reduced Matrigel (an extracellular matrix) for 10 d to exam-
ine morphological differentiation in three dimensions. Cells
grown in serum-free media containing insulin and hydro-
cortisone grew as disorganized colonies, consisting of 14.8 
4.5 cells per colony on average (Figure 2A). Addition of PRL
reduced the number of cells per colony (10.7  4.2) and
resulted in the organization of cells into a single cell layer
surrounding a single lumen.
The addition of EGF to HC11 cells in 3D culture for 10 d
resulted in increased cell number per colony (38.6  9.1) com-
pared with untreated controls (Figure 2B). The EGF-treated
colonies remained cellular masses without lumens. The EGF-
induced increase in cell number per colony was inhibited by
the addition of the ErbB1/ErbB2 inhibitor GW572016 at 0.5 M
(12.8  3.8 cells per colony; Figure 2B). Similar to PRL, addition
of HB-EGF decreased the number of cells per colony (9.4  3.2)
compared with untreated controls and resulted in the organi-
Figure 2. ErbB4 activity is required for 3D
lumen formation. (A) 3D culture of HC11 cells
in growth factor-reduced Matrigel  PRL.
Cells were cultured 10 d, stained with DAPI,
and photographed using a Zeiss LCM-210;
DAPI and DIC images are shown. Arrows in-
dicate lumen formation. Scale bars, 25 m. (B)
3D culture of HC11 cells in growth factor-
reduced Matrigel  EGF, HB-EGF, or HRG,
and GW572016 (0.5 M). Cells were cul-
tured 10 d, stained with DAPI, and photo-
graphed using a Zeiss LCM-210; DAPI and
DIC images are shown. Arrows indicate lu-
men formation. Scale bars, 25 m. (C) HC11
cells were serum/EGF-starved in the presence
or absence of increasing concentrations of
GW572016 (0–10 M) for 16 h, and treated for
30 min with HB-EGF or HRG. ErbB1, ErbB2,
ErbB3, and ErbB4 immunoprecipitates (IPs)
were analyzed by immunoblot for phosphoty-
rosine.
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zation of cells into a single epithelial layer surrounding a lu-
men. Lumen formation in response to HB-EGF was not inhib-
ited by 0.5 M GW572016. HRG increased the number of cells
per colony (36.9  11.6) compared with untreated controls and
caused colonies to grow as branched, solid cords. The in-
creased growth of HRG-treated cells was inhibited by 0.5 M
GW572016 (16.8  7.2; Figure 2B). Interestingly, HRG-treated
cultures grown with 0.5 M GW572016 formed multilobulated
structures comprised of a single-cell layer surrounding multi-
ple lumens. This suggests that reduction in HER2 signaling
(see below) allows the HRG-dependent HER4 morphological
differentiation signal to predominate.
Published data indicate that GW572016 inhibits human
ErbB1 and ErbB2 enzymatic activity more potently than it
does ErbB4 (5–10-fold higher Ki; Xia et al., 2002), but this has
not been tested with regard to mouse ErbB receptors. We
incubated cells with increasing concentrations of GW572016
for 16 h, treated cells with HRG or HB-EGF for 30 min, and
examined receptor phosphorylation. Treatment of HC11
cells with GW572016 at 0.1 M significantly inhibited ErbB1
and ErbB2 tyrosine phosphorylation and at 0.5 M reduced
tyrosine phosphorylation of ErbB3, but not that of ErbB4
(Figure 2C). Note that ErbB3 is itself devoid of tyrosine
kinase activity, but supports the activity of other ErbB re-
ceptors. ErbB4 tyrosine phosphorylation was observed with
concentrations of GW572016 as high as 5 M. Although
EGF-dependent activation of p44/42 MAP kinase was inhib-
ited in cells treated with 0.5 M GW572016, PRL-mediated
MAP kinase activation was not impaired by GW572016 (un-
published data), demonstrating the specificity of the inhib-
itor. GW572016 (0.5 M) did not impair lumen formation by
HB-EGF and actually enhanced it in HRG-treated cells; this
suggests that ErbB4, but not ErbB1 or ErbB2, plays a prom-
inent role in structural differentiation of mammary epithelial
cells in response to these ligands.
Differentiation of HC11 Cells Is Induced by Expression of
s80HER4
Previous reports demonstrate that ErbB4 undergoes HRG-
inducible proteolytic processing, releasing the soluble ErbB4
80-kDa intracellular domain (s80HER4) into the cytoplasm.
We determined if HB-EGF or HRG could result in cleavage
of endogenous ErbB4 to generate s80HER4 by treating serum-
starved HC11 cells with ligand (30 min) and then analyzing
ErbB4 immunoprecipitates by Western blot with an anti-
body against the ErbB4 intracellular domain. A single im-
munoreactive species was detected at 180 kDa in untreated
cells, consistent with the size of endogenous ErbB4 (Figure
3A). Within 30 min of HRG treatment, 180- and 80-kDa
immunoreactive products were identified. To a lesser extent,
HB-EGF induced the formation of the 80-kDa product; we
were unable to detect the 80-kDa isoform in response to PRL
after 30 min.
HC11 cells were stably transfected with a cDNA encoding
the entire intracellular domain of human HER4 in frame
with green fluorescent protein (GFP; Figure 3B). The GFP tag
was at the NH2-terminus of s80HER4, so as not to disrupt the
COOH-terminal PDZ-binding domain, which may be im-
portant in signaling (Ni et al., 2003). In these cells, GFP-
s80HER4 was constitutively tyrosine phosphorylated (Figure
3B), consistent with recent reports that s80HER4 is a consti-
tutively active tyrosine kinase capable of autophosphoryla-
tion (Linggi et al., 2005); however, endogenous full-length
ErbB4 was not basally phosphorylated by GFP-s80HER4, nor
Figure 3. Expression of s80HER4 induces li-
gand-independent STAT5A phosphorylation.
(A) HC11 cells serum-starved overnight, treated
with PRL, HRG, or HB-EGF for 30 min. ErbB4
was immunoprecipitated with a polyclonal
ErbB4 antibody; immunocomplexes were ana-
lyzed by Western blot using a monoclonal ErbB4
antibody. Molecular weights (kDa) are indicated
at left. The predicted sizes of the membrane
bound full-length ErbB4/HER4 and an 80-kDa
cleavage product that is either membrane-
bound or soluble (m80HER4/s80HER4) are indi-
cated at right. (B) HC11 cells were stably trans-
fected with pcDNA4 or pcDNA4-s80, encoding
GFP-tagged s80HER4. Pooled clones of stably
transfected cells were grown in serum-free me-
dia overnight and then treated  HB-EGF for 30
min. ErbB4 was immunoprecipitated using a
polyclonal antibody. Immunoprecipitates were
analyzed by Western with an antibody against
phosphotyrosine. (C) Western analysis to detect
tyrosine phosphorylation of ErbB1, ErbB2, or
ErbB3 immunoprecipitates from HC11-GFP-s80
cells treated  EGF or HRG where indicated.
(D) Pools of HC11-pcDNA4 or HC11-GFP-s80
cells were serum-starved and then treated with
PRL or HB-EGF for 30 min. Western analysis of
ErbB4 or GFP immunoprecipitates to detect
phosphotyrosine resides; Western analysis of
STAT5A immunoprecipitates to detect total
STAT5A and phosphotyrosine 694 STAT5A/B.
(E) 3D culture of HC11 cells in growth factor-
reduced Matrigel  PRL. Cells were cultured
10 d, stained with DAPI, and photographed;
DAPI and DIC images are shown. Arrows indi-
cate lumen formation.
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did GFP-s80HER4 expression interfere with or enhance full-
length ErbB4 phosphorylation in response to HB-EGF. Phos-
phorylation of ErbB1 in response to EGF or of ErbB2 and
ErbB3 in response to HRG was not affected by expression of
GFP-s80HER4 in HC11 cells (Figure 3C), nor was GFP-
s80HER4 found to coprecipitate with ErbB1, -2, or -3 (Figure
3C and unpublished data). Although PRL induced the Tyr-
694 phosphorylation of STAT5 in HC11-pcDNA4 cells,
STAT5A phosphorylation was not detected in untreated
HC11-pcDNA4 cells (Figure 3D), similar to parental HC11
cells (see Figure 1A). In contrast, constitutive STAT5A phos-
phorylation was seen in HC11-GFP-s80 cells in the absence
of exogenous ligand (Figure 3D). This suggests that expres-
sion of s80HER4 is sufficient to induce STAT5A phosphory-
lation under basal conditions. Interestingly, these studies
found that ErbB4 became tyrosine phosphorylated in re-
sponse to PRL, although the mechanism for this is currently
unknown (Figure 3D).
In 3D Matrigel cultures, HC11-pcDNA4 cells formed dis-
organized colonies in the absence of additional factors (Fig-
ure 3E), similar to untreated parental HC11 cells (as shown
in Figure 2A). HC11-GFP-s80 cells grown in 3D colonies
formed rudimentary lumens in the absence of exogenous
ligand (Figure 3E) and contained fewer cells than untreated
HC11-pcDNA4 cells (9.1  2.6 vs. 14.8  4.5, respectively;
p  0.02, Student’s unpaired t test). Lumen formation was
enhanced by the addition of exogenous PRL, without statis-
tically altering the number of cells per colony versus un-
treated GFP-s80HER4 cells (8.3  3.4; p  0.26, Student’s t
test). These results suggest that expression of s80HER4 leads
to growth inhibition and enhances acinar formation of HC11
cells in 3D cultures.
Kinase Activity of s80HER4 Is Required for Nuclear
Translocation and STAT5A Activation
We constructed pcDNA4-s80KD, encoding GFP-tagged ki-
nase-dead s80HER4 (s80KD), harboring a single Lysine 751 to
Arginine point mutation in the ATP-binding pocket to dis-
rupt kinase activity. Stable transfection of HC11 cells with
this construct generated HC11-GFP-s80KD cells. Although
GFP-s80HER4 was tyrosine phosphorylated in the presence
or absence of HB-EGF, GFP-s80KD was not basally tyrosine
phosphorylated, nor was it tyrosine phosphorylated in cells
treated with HB-EGF for up to 96 h (Figure 4A). This is
consistent with a recent report demonstrating that Lys 751 to
Ala mutation within s80HER4 impairs tyrosine phosphoryla-
tion in vivo and kinase activity in vitro (Linggi et al., 2005).
Although GFP-s80KD was not tyrosine phosphorylated, ex-
pression of GFP-s80KD did not interfere with ligand-induced
tyrosine phosphorylation of full-length ErbB4 or ErbB1,
ErbB2, or ErbB3 (Figure 4B). Consistent with previous re-
ports describing nuclear localization of s80HER4, GFP fluo-
rescence of live cells revealed cytoplasmic and nuclear lo-
calization of GFP-s80HER4 (Figure 4C). In contrast, GFP-
s80KD was strictly localized to the cytoplasmic compartment
Figure 4. Kinase activity of s80HER4 is re-
quired for its nuclear localization and tyro-
sine phosphorylation. (A) HC11-GFP-s80 and
HC11-GFP-s80KD cells were serum-starved
overnight and then treated with HB-EGF for
0–96 h. IP was performed using an anti-HER4
polyclonal antibody and then analyzed by IB
for phosphotyrosine. Blots were stripped and
reprobed with a monoclonal anti-HER4 anti-
body. n.s., nonspecific band. (B) HC11-GFP-
s80KD cells were serum-starved overnight and
then treated  ligand for 30 min before the
immunoprecipitation of ErbB1, -2, -3, and -4
from low-salt lysates. Immunoprecipitates
were analyzed by Western analysis with a
phosphotyrosine antibody. (C) HC11-GFP-s80
and HC11-GFP-s80KD cells were analyzed for
expression of GFP by live cell fluorescence
microscopy. (D) HC11-GFP-s80 and HC11-
GFP-s80KD cells were separated into cytoplas-
mic and nuclear fractions, which were ana-
lyzed by Western analysis using HER4, c-jun,
and 14–3-3 antibodies. (E) HC11 cells were
transiently transfected with pcDNA4-s80 (not
GFP-tagged), pcDNA4-GFP-s80KD, or with
both together. Cells were separated in cyto-
plasmic and nuclear fractions then analyzed
by Western blot with antibodies against ErbB4
and p107. (F) Immunofluorescence detection
of STAT5A in HC11-GFP-s80 and HC11-GFP-
s80KD cells.
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of cells. Biochemical separation of HC11-GFP-s80KD cells
into nuclear and cytoplasmic compartments also revealed
that GFP-s80KD was strictly limited to the cytoplasm, but
that GFP-s80HER4 was present in both nuclei and cytoplasm
(Figure 4D). This is the first demonstration that kinase ac-
tivity of s80HER4 is required for its nuclear translocation. To
determine if kinase-dead GFP-s80KD could translocate to the
nucleus in the presence of active s80HER4, we coexpressed an
untagged s80 together with GFP-tagged s80KD (Figure 4E).
Although untagged s80HER4 was found in both nuclear and
cytoplasmic compartments, GFP-s80KD was never detected
in the nucleus, regardless of coexpression with s80HER4,
confirming that kinase activity of s80 is required for its
nuclear localization. Immunofluorescent localization of
phopsho-STAT5 was examined in HC11-GFP-s80 and HC11-
GFP-s80KD cells. Although 16.7  3.4% of HC11-GFP-s80
cells displayed basal nuclear localization of phospho-STAT5,
nuclear localization of phospho-STAT5 was not detected in
HC11-GFP-s80KD cells (Figure 4F).
STAT5A immunoprecipitates were examined by Western
analysis to detect a potential STAT5A-s80HER4 association.
Although STAT5A coprecipitated with GFP-s80HER4 from
HC11-GFP-s80 cells, GFP-s80KD was not detected in
STAT5A immunocomplexes (Figure 5A), despite equal lev-
els of STAT5A immunoprecipitation. This is consistent with
the idea that SH2-domains within STAT5A mediate interac-
tions with phosphotyrosine residues within ErbB4. We ex-
amined STAT5A-mediated transcription using the pcasein-
lux reporter in parental HC11 cells (Figure 5B). Expression of
GFP-s80HER4 resulted in a 12.6-fold increase in luciferase
activity in the absence of ligand. In contrast, expression of
the kinase-dead GFP-s80KD was unable to increase luciferase
activity, even though GFP-s80HER4 and GFP-s80KD were
expressed at similar levels. These data suggest that kinase
activity is critical for ligand-free, s80HER4-mediated activa-
tion of this STAT5-dependent promoter.
Endogenous -casein gene expression was examined in
HC11-GFP-s80HER4 cells (Figure 5C). -casein mRNA was
detected in HC11-pcDNA4 cells treated with PRL, but not in
untreated cells. However, -casein expression was detected
in untreated HC11-GFP-s80HER4 cells and was further ele-
vated with PRL. In contrast, HC11-GFP-s80KD cells did not
exhibit basal expression of -casein, whereas PRL-induced
expression of -casein was observed in HC11-GFP-s80KD
cells (Figure 5D). These results suggest that kinase activity of
s80HER4 is required for STAT5A-mediated differentiation.
Because tyrosine kinase activity is required for both s80HER4
nuclear localization and for interaction with STAT5A, it is
possible that inhibition of s80HER4 nuclear localization per se
would be sufficient to impair STAT5A nuclear localization
and transcriptional activation.
Differentiation of HC11 Cells Requires Transmembrane
Cleavage of ErbB4
The human and mouse ErbB4 transmembrane domains har-
bor a canonical -secretase cleavage sequence also found in
Notch and amyloid precursor protein (APP), among others
(Carpenter, 2003). In proteins that are processed by -secre-
tase, the P1 Val residue (nearest the cytoplasmic domain) is
critical for -secretase–mediated processing, such that its
mutation abolishes transmembrane cleavage by -secretase.
We generated a Val 675 (the P1 Val) to Ala point mutation
within the transmembrane domain of human ErbB4/HER4
(JMa/Cyt-1 isoform) in pLXSN, thus eliminating the puta-
tive ErbB4 -secretase cleavage site. Wild-type human
HER4, kinase-dead HER4KD (Sartor et al., 2001), and
HER4VA were overexpressed in pooled clones of HC11 cells
by stable transfection (Figure 6A). We treated serum-starved
HC11-HER4, HC11-HER4KD, and HC11-HER4VA cells with
HB-EGF (30 min) and then separated cells into membrane
and cytosolic fractions (Figure 6A). The 180- and 80-kDa
ErbB4 products were detected in membrane preparations of
HC11-HER4. We observed an accumulation of the 80-kDa
ErbB4 product in membrane preparations of HC11-HER4VA
cells. In contrast, only the 180-kDa isoform of ErbB4 was
detected in cells expressing HER4KD. This is consistent with
previous reports that preliminary cleavage events may re-
Figure 5. Expression of s80HER4 is sufficient to
induce differentiation of HC11 cells. (A) Low-
salt lysates (125 mM NaCl) of cells grown in
serum-free media were immunoprecipitated
with a monoclonal STAT5A antibody. Immuno-
precipitates were analyzed by Western using a
rabbit GFP antibody or a mouse STAT5A anti-
body. (B) Cells were transiently transfected with
pcasein-lux and then treated  PRL or HB-
EGF (HC11-pcDNA4 cells only) or were main-
tained in serum-free media for the final 24 h of
culture. Top, luciferase activity was determined
as described above. *p  0.001. Student’s t test.
n  3. Top, Western analysis of cell extracts
using a GFP antibody detected GFP-tagged
s80HER4 or s80KD (top); Western analysis using a
STAT5A antibody demonstrated equal amounts
of STAT5A in each lane (bottom). (C and D)
RT-PCR analysis to detect expression of -casein
or K18. (C) HC11-pcDNA4 and HC11-GFP-s80
were cells grown to confluence, serum-starved,
and then treated for 2 d in the presence or ab-
sence of PRL. Where indicated, water was
added to the RT-PCR reaction as a negative con-
trol. (D) RNA harvested from HC11-GFP-s80
and HC11-GFP-s80KD cultured  PRL were an-
alyzed for expression of K18 or -casein as de-
scribed above.
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quire kinase activity of ErbB4. Although membrane-bound
80-kDa ErbB4 was detected in HC11-HER4 and to a lesser
extent in HC11-HER4VA cells, cytoplasmic 80-kDa ErbB4
was only detected in HC11-HER4 cells, suggesting that the
-secretase cleavage site was altered by mutation of Val 675.
This is similar to results of other groups, in which a Val to Ile
point mutation was introduced into the human HER4 se-
quence at Val 673 (Vidal et al., 2005). Other groups have also
shown the accumulation of a membrane bound 80-kDa
HER4 product when cells were treated with a chemical
-secretase inhibitor, which inhibited the formation of solu-
ble s80HER4 (Maatta et al., 2006).
ErbB1-4 immunoprecipitates from HC11-HER4VA cells
were examined for tyrosine phosphorylation by Western
analysis. EGF increased tyrosine phosphorylation of ErbB1
(Figure 6B), whereas HRG increased tyrosine phosphoryla-
tion of ErbB2 and ErbB3. Basal levels ErbB4 tyrosine phos-
phorylation were observed and may reflect the high level of
ErbB4/HER4 expression in these cells.
Immunofluorescence detecting ErbB4/HER4 was used to
examine its subcellular localization. ErbB4 was below the
level of detection in HC11-pLXSN cells (Figure 6C). In the
absence of stimulation, ErbB4/HER4 was diffusely cytoplas-
mic in HC11-HER4 and HC11-HER4VA cells, but was cyto-
plasmic and nuclear in HC11-s80 cells (Figure 6C, top pan-
els). Although treatment of HC11-HER4 cells with HB-EGF
resulted in nuclear accumulation of ErbB4 in 28.9  6.4% of
all cells, ErbB4 was never detected in the nucleus of HC11-
HER4VA cells in response to HB-EGF (Figure 6C, bottom
panels), nor was nuclear ErbB4 detected in TPA-treated
HC11-HER4VA cells (unpublished data).
HC11-HER4VA cells displayed STAT5A phosphorylation in
response to PRL and HB-EGF (Figure 7A). However, STAT5-
dependent transcription in HC11-HER4VA cells was impaired
in response to HB-EGF compared with HC11-HER4 cells, de-
spite equal levels of HER4/ErbB4 expression in each cell line
(Figure 7B). Additionally, PRL-induced transcription was
moderately decreased in HC11-HER4VA cells compared with
Figure 6. A cleavage of ErbB4 is required for differen-
tiation of HC11 cells. (A) Pools of HC11 cells stably
transfected with pLXSN-HER4, -HER4KD, or -HER4VA
were cultured overnight in serum-free media and
treated for 30 min with HB-EGF. Membrane and cyto-
plasmic extracts were fractionated and analyzed by im-
munoblot (IB) using an ErbB4 mAb (Neomarkers). Mo-
lecular weights are shown at left. n.s., nonspecific band.
(B) Western analysis to detect tyrosine phosphorylation
of ErbB1, -2, -3, and -4 IPs from serum-starved HC11-
HER4VA cells treated with EGF (ErbB1) or HRG
(ErbB2–4) for 10 min. (C) Serum-starved cells cultured
30 min  HB-EGF. Arrows indicate nuclear localization.
DAPI staining of nuclei is shown in bottom panels.
Indirect immunofluorescence to detect ErbB4 is shown
in the top panels.
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HC11-HER4 cells. Although keratin 18 mRNA was constitu-
tively expressed in HC11-HER4VA cells, the induced expres-
sion of -casein mRNA was not observed in response to HB-
EGF or PRL (Figure 7C). Although HB-EGF induced the
expression of -casein protein in HC11-HER4 cells, -casein
was not detected in protein extracts from HB-EGF–treated
HC11-HER4VA cells (Figure 7D). Finally, HC11-HER4 cells
were able to organize into lumen-containing structures in Ma-
trigel supplemented with HB-EGF, whereas HC11-HER4VA
cells continued to grow as disorganized colonies in the pres-
ence of HB-EGF (Figure 7E). Taken together, all the results
suggest that s80HER4 production from ErbB4 is necessary to
elicit full differentiation of mammary epithelial cells in re-
sponse to ErbB4 ligands. These data are consistent with reports
from others suggesting s80HER4 may act as a nuclear chaperone
to STAT5A, because HER4VA does not allow for nuclear trans-
location of the ErbB4 intracellular domain (Williams et al.,
2004).
STAT5A Activation via s80HER4 Does Not Require the
16-Amino Acid Region Specific for the s80Cyt1 Variant,
but Lacking in the s80Cyt2 Splice Variant
Two intracellular ErbB4 splice variants have been described,
Cyt1 (encoding the entire intracellular domain) and Cyt2,
which lacks a 16-amino acid sequence (Figure 8A; Kainu-
lainen et al., 2000). All data presented thus far are from
experiments using the Cyt1 isoform, referred to as s80HER4.
To determine if the 16 amino acids present in s80HER4 but
absent in s80Cyt2 are required for s80HER4-mediated STAT5A
activation, we expressed s80Cyt2 in HC11 cells by stable
transfection with pcDNA4-s80Cyt2 (Figure 8B). As with GFP-
s80HER4, constitutive tyrosine phosphorylation of s80Cyt2
was observed (note that s80Cyt2 was not tagged with GFP).
Also like GFP-s80HER4, expression of s80Cyt2 resulted in
basal, ligand-free Tyr-694 phosphorylation of STAT5A,
whereas HC11-pcDNA4 cells displayed only ligand-depen-
dent STAT5A phosphorylation (Figure 8B). We also ob-
served nuclear localization of s80Cyt2 (Figure 8C). Nuclear
STAT5A was detected in untreated HC11-s80Cyt2 cells, albeit
at lower levels than what was seen in HC11-GFP-s80 cells.
Although this observation may be due to intrinsic differ-
ences between s80HER4 and s80Cyt2, it is possible that this
may have been due to the observed lower expression levels
of s80Cyt2 compared with GFP-s80HER4. We examined
STAT5A-mediated transcription using the pcasein-lux re-
porter in parental HC11 cells (Figure 8D). Expression of
GFP-s80HER4 resulted in a 11.1-fold increase in luciferase
activity in the absence of ligand, whereas expression of
s80Cyt2 increased luciferase activity 8.8-fold higher than un-
treated HC11-pcDNA4 cells. These data suggest that the
16-amino acid sequence absent in s80Cyt2 is not necessary for
Figure 7. Cleavage of ErbB4 at V675 is re-
quired for ErbB4-mediated differentiation. (A)
Pooled clones of HC11-HER4VA cells were se-
rum-starved overnight and then treated for 30
min with PRL or HB-EGF. STAT5A immuno-
precipitates (IP) were analyzed by immuno-
blot (IB) to detect phospho-STAT5A/B or
STAT5A. (B) HC11-HER4 and HC11-HER4VA
cells were transiently transfected with pcasein-
lux. Cells remained in serum-free media or
were treated with the indicated factors for the
final 24 h of the experiment. Luciferase activity
was determined in extracts as described above
(top panel). Extracts were further examined
for total levels of HER4/ErbB4 expression by
immunoblot using a monoclonal ErbB4 anti-
body (bottom panel). (C) RT-PCR analysis to
detect expression of -casein or K18 in HC11
or HC11-HER4VA cells treated with PRL or
HB-EGF (HB). (D) Western analysis to detect
expression of total HER4 levels and -casein
or -tubulin in extracts from HC11-HER4 and
HC11-HER4VA cells cultured in priming me-
dia for 48 h and then in priming media 
HB-EGF for an additional 48 h. (E) 3D culture
of HC11-HER4 or HC11-HER4VA cells grown
in growth factor-reduced Matrigel in the pres-
ence of HB-EGF for 10 d. Arrow indicates
lumen formation. DAPI and DIC images are
shown.
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s80HER4-mediated activation of this STAT5-dependent pro-
moter.
DISCUSSION
Genetically engineered mouse models demonstrate that
ErbB4 is required for mammary differentiation and STAT5A
activation (Jones et al., 1999; Long et al., 2003; Tidcombe et al.,
2003). However, the mechanism by which the ErbB4 path-
way signals differentiation has not been well-defined. Using
an ex vivo model of differentiation, we demonstrate that
ErbB4 signaling induces mammary cell differentiation and
that ligand-induced cleavage to a soluble, intracellular/nu-
clear fragment is both necessary and sufficient to trigger
differentiation in response to ErbB4 ligands.
Although the biochemical details of ErbB4 proteolytic pro-
cessing resulting in ErbB4 ectodomain shedding and nuclear
accumulation of s80HER4 have been known and nuclear
ErbB4 has been observed in many cell types, the identifica-
tion of a physiological role for s80HER4 has remained elusive.
Our results demonstrate that one function of s80HER4 is to
direct STAT5A-mediated lactogenic differentiation in re-
sponse to ErbB4 ligands. Previous reports suggest that nu-
clear accumulation of the ErbB4 intracellular domain (ICD)
may be required for STAT5A-mediated transcription in tran-
sient reporter systems. It is known that the carboxy-terminal
acidic regions of ErbB4, as well as ErbB1 and ErbB2, contain
an intrinsic transactivation function and are able to transac-
tivate a GAL4-VP16 luciferase-based reporter system (Lin et
al., 2001; Ni et al., 2001; Wang et al., 2004). Our results using
the HC11 model of mammary differentiation extend these
findings to include multiple physiological aspects of lacto-
genic differentiation, such as endogenous milk protein ex-
pression and structural acinar formation in three dimen-
sions, underscoring the physiological relevance of s80HER4.
Expression of s80HER4 is detected in the nucleus and cy-
toplasm of HC11 cells and in human breast cancer samples,
consistent with the presence of protein sequences within
s80HER4 that govern nuclear import and export and suggest-
ing a complex pattern of intracellular shuttling that we are
only beginning to understand. At least one factor that reg-
ulates nuclear accumulation of s80HER4 is its tyrosine kinase
activity, because kinase-dead GFP-s80KD was strictly re-
stricted to the cytoplasm of cells, as shown using live cell
fluorescence (Figure 4C) and biochemically (Figure 4D). The
mechanism by which the kinase domain of s80HER4 dictates
nuclear localization is unknown, but one possibility is that
tyrosine phosphorylation of s80HER4 facilitates its associa-
tion with a nuclear importin or somehow facilitates the
retention of s80HER4 within the nucleus. Kinase activity of
s80HER4 was also required for ligand-free phosphorylation
and nuclear translocation of STAT5A. The idea that s80HER4
functions as a nuclear chaperone for STAT5A has been pre-
viously reported in studies in which mutation of a nuclear
localization sequence within s80HER4 completely impaired
STAT5A nuclear translocation (Williams et al., 2004). The
results presented here are not inconsistent with this, in that
cytoplasmic retention of GFP-s80KD also correlated with
cytoplasmic retention of STAT5A. However, it is not yet
clear if it is loss of nuclear localization, loss of kinase activity
per se, or loss of both together that prevents the ligand-free
nuclear accumulation of STAT5A in HC11-GFP-s80KD cells.
Lactogenic gene expression and morphological changes in
three dimensions were induced either by PRL, HRG, or HB-
EGF (Figure 2). Although HB-EGF stimulates both ErbB1 and
ErbB4, inhibition of ErbB1 (using 0.5 mM GW572016) did not
impair differentiation; in contrast, inhibition of ErbB4 activity
(by overexpression of kinase-dead HER4KD) blocked differen-
tiation of HC11 cells in response to HB-EGF. Similarly, HRG-
induced activation of ErbB2 was unnecessary and may even
inhibit structural differentiation of HC11 cells, because
GW572016-mediated inhibition of ErbB2 allowed HC11 lumen
formation in Matrigel. Interestingly, when allowed to proceed
in the absence of the ErbB inhibitor, HRG-mediated stimula-
tion of ErbB2, ErbB3, and ErbB4 tyrosine kinase activity in-
creased the cellular content of HC11 colonies and induced the
formation of multilobulated solid cords of cells. The summary
effect of HRG on morphological structure appears, then, to
depend on the complex ratio of ErbB2 to ErbB4 signaling. For
example, inhibition of ErbB2 in the presence of HRG-depen-
dent ErbB4 signal allowed a level of HRG/ErbB4-dependent
lumen formation and differentiation. ErbB2-mediated morpho-
logical changes in three dimensions have been demonstrated
by others using MCF10A cells (Muthuswamy et al., 2001).
Figure 8. Expression of s80Cyt2 induces
STAT5A activity in HC11 cells. (A) Schematic
diagram of s80HER4 (i.e., the intracellular do-
main of HER4) indicating the two naturally
occurring cytoplasmic splice variants of hu-
man ErbB4/HER4. (B) Western analyses of
ErbB4 or STAT5A immunoprecipitates from
cells cultured overnight in serum-free media
and then treated  HB-EGF for 30 min. ErbB4
immunoprecipitates (made with a polyclonal
ErbB4 antibody) were analyzed by Western
with a monoclonal ErbB4 antibody. Stat5A
immunoprecipitates were analyzed by West-
ern with antibodies against phospho-STAT5
or STAT5A. (C) HC11-s80 and HC11-s80Cyt2
cells were separated into cytoplasmic and nu-
clear lysates, which were used for immuno-
precipitation (described below) or directly for
Western with an antibody against phospho-
c-jun. ErbB4 immunoprecipitates were ana-
lyzed by Western analysis for phospho-ty-
rosine; STAT5A immunoprecipitates were
analyzed by Western for phospho-STAT5. (D)
Cells (indicated in legend) were transiently transfected with pCasein-lux. Cells were maintained in serum-free media for the final 24 h of
culture. Luciferase activity was measured as described above. n  3.
Nuclear ErbB4 Differentiates HC11 Cells
Vol. 17, September 2006 4127
Each of the ErbB receptors has been observed within
nuclei. ErbB1 (Lin et al., 2001), ErbB2 (Wang et al., 2004), and
ErbB3 (Offterdinger et al., 2002) have been reported to trans-
locate to the nucleus upon ligand stimulation as full-length
proteins. In contrast, a proteolytic fragment of ErbB4 with an
active tyrosine kinase is known to localize to the nucleus, but
not the entire receptor. ErbB4 is first processed by TACE and
next by -secretase. We demonstrate that the resulting pro-
teolytic fragment, s80HER4, accumulated in the nuclei of
mammary epithelial cells, induced STAT5A phosphoryla-
tion and expression of -casein and stimulated acinar lumen
formation. The requirement for ligand-inducible proteolysis
of ErbB4 was demonstrated by the V675A mutation in the
-secretase cleavage site of ErbB4, which impaired cytoplas-
mic release and nuclear accumulation of ErbB4, and at the
same time impaired the biological consequences of ErbB4
signaling in HC11 cells. ErbB4 signaling from the V675A
mutant may mimic the signaling effects of the JMb splice
variant of ErbB4, which lacks the short juxtamembrane
TACE cleavage site, and therefore cannot produce s80HER4.
Given the role of ErbB4 in mammary gland development
and the effects of ErbB4 proteolysis on downstream signal-
ing, the balance of JMa versus JMb variants could have
important physiological implications in development, differ-
entiation, and cancer of the mammary gland.
Our results presented here suggest that ErbB4 may differ-
entiate mammary cells through nuclear accumulation of
s80HER4, thus identifying a physiological role for nuclear
ErbB4 and supporting a mechanism by which ErbB4 differ-
entiates the mammary epithelium.
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